Abstract

A positive diagnostic strategy is safe and saves endoscopies in patients with irritable bowel syndrome: A five-year follow-up of a randomized controlled trial

Neurogastroenterol Motil. 2020 Oct 7;e14004. doi: 10.1111/nmo.14004. Online ahead of print.

Anne Line Engsbro 1 2, Luise M Begtrup 3 4, Peter Haastrup 4, Maria Munch Storsveen 4, Peter Bytzer 1, Jens Kjeldsen 5, Ove Schaffalitzky De Muckadell 5, Dorte Ejg Jarbøl 4

 
     

Author information

  • 1Department of Medicine, Zealand University Hospital, Køge and Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
  • 2Department of Clinical Microbiology, University Hospital Copenhagen Hvidovre, Hvidovre, Denmark.
  • 3Department of Occupational and Environmental Medicine, Bispebjerg and Frederiksberg Hospital, København, Denmark.
  • 4Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • 5Department of Medical Gastroenterology S, Odense University Hospital, Odense, Denmark.

Abstract

Background: Previously, the diagnosis of irritable bowel syndrome (IBS) required exclusion of organic causes by extensive diagnostic testing. Newer guidelines recommend IBS as a positive diagnosis based on symptoms with limited testing. We investigated the long-term safety and impact on use of health resources of a positive diagnostic strategy compared to a strategy of exclusion in patients with symptoms compatible with IBS.

Methods: In 2008-2010, primary care patients aged 18-50 years fulfilling the Rome III criteria for IBS without alarm signals were randomized to a positive diagnostic strategy (limited blood tests, n = 150) or a strategy of exclusion (extensive blood tests, fecal samples for intestinal parasites, and sigmoidoscopy with biopsies, n = 152). At five years, hospital-registered diagnoses and use of health resources including lower endoscopies were retrieved from national registries. Participants provided 5-year data on Rome III criteria for IBS, severity of symptoms, and quality of life.

Key results: Baseline mean age was 31.4 (SD 9.1) years; 79% were female. No cases of celiac disease, and gastrointestinal or gynecological cancers were diagnosed within five years. Negligible and comparable numbers were diagnosed with inflammatory bowel disease, benign gynecological conditions, and upper GI conditions in the two groups. The positive diagnosis strategy carried a higher number of lower endoscopies from year 1 to 5 (23 patients versus 13 patients in the exclusion group), but overall saved endoscopies.

Conclusions & inferences: A positive diagnosis of IBS was as safe as a diagnosis of exclusion in a five-year perspective and saved lower endoscopies; the study was registered at ClinicalTrials.gov numbers: NCT00659763/NCT01153295.

© Copyright 2013-2020 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.